Hemoadsorption for Severe Ischemic Stroke

This is a multicenter, randomized-controlled, open-label, blinded endpoint clinical trial that aims to evaluate the efficacy and safety of hemoadsorption for severe ischemic stroke

Inclusion Criteria: 1.18 years ≤ age \< 80 years; 2.Pre-stroke mRS score ≤ 1; 3.Anterior circulation cerebral infarction within 48 hours of onset, meeting at least one of the following: 1. 15≤ NIHSS score ≤32; 2. 3\1/2 of the MCA territory; 4.hs-CRP ≥2 mg/L at randomization; 5.If reperfusion therapy is performed, no improvement in NIHSS score (still ≤32) post-treatment; 6.Signed informed consent obtained. Exclusion Criteria: 1. Hemorrhagic transformation of PH2 type prior to randomization; 2. Brain herniation or decompressive craniectomy performed before randomization; 3. Hemodynamic instability refractory to medical correction (systolic blood pressure \2 times the upper limit of normal) and renal impairment (defined as serum creatinine \>1.5 times the upper limit of normal or estimated glomerular filtration rate \[eGFR\] \